CHD-101

CHD-101 is an optimized next-generation cyclodextrin-based drug candidate developed by CarboHyde. It is being advanced for the treatment of a rare genetic disease with unmet medical need, and represents a novel approach leveraging carbohydrate chemistry to address rare diseases. The drug is currently in preclinical development and is part of CarboHyde’s pipeline focused on innovative cyclodextrin derivatives for various indications, including neurodegenerative and other rare diseases. The specific mechanism of action has not been disclosed, but it is described as a chemical drug with an optimized cyclodextrin structure designed to improve therapeutic outcomes in its target indication[1][3].